Oestrogens, such as 17b-oestradiol (E 2 ), have pleiotropic effects throughout the body, owing, in part, to their having several sources and target tissues. E 2 is primarily thought of as being produced and secreted by the ovaries, and influencing reproduction-related function. In addition to a clear ovarian source, E 2 is also produced in other regions of the body, including the adrenal glands, adipose and the central nervous system (CNS) (1). One challenge is that many of these sources of oestrogens are also a main target of them for their diverse trophic effects (e.g. the brain, ovaries) throughout the lifespan. Furthermore, the diverse effects of E 2 are not limited to reproductive function, and can influence mood and cognition. The effects of E 2 are not limited to a discrete time period but have actions throughout the lifespan, from development to late age. It is beyond the scope of this review to exhaustively cover all sources of E 2 , as well as its targets, effects and the timing of the influence of E 2 . Instead, this review will focus on the possibility that the beneficial effects of E 2 in the brain at oestrogen receptor (ER)b, may be distinguishable from the negative proliferative effects on peripheral, ERa-rich tissues, such as the uterus and mammary glands. Basic science experiments performed in our laboratory and others in support of this notion will be reviewed and discussed. More recent lines of investigation aiming to further understand the mechanisms of the effects of E 2 at ERs, which may involve changes in the cell cycle, will be summarised. What follows first is a brief summary of the most well-recognised physical and psychological effects of E 2 throughout the adult lifespan.
Menopause
The hallmark of menopause is decline in E 2 production from the ovaries. Physical and psychological symptoms of decline in E 2 production and response with age and menopause uncover a role of E 2 for these functions. Symptoms can include changes in cardiovascular control, hot flashes, night sweats, drying of mucosal membranes, changes in bone mass maintenance that can increase risk of osteoporosis and psychological effects, such as sleeplessness, forgetfulness, anxiety, depression and cognitive changes. Studies demonstrate that certain symptoms of E 2 decline can be alleviated with synthetic E 2 therapies. However, there is considerable individual variability in these positive effects leaving many women with few physical and psychological benefits. Furthermore, in the large Women's Health Initiative clinical trials, there were potentially deleterious side effects related to E 2 therapy, such as increased risk of stroke and ⁄ or reproductive tissue cancers (e.g. uterus, breast) (9, 10) . These findings of a lack of effect and deleterious effects of E 2 are surprising. Rodent models of menopausal decline in E 2 , such as ageing models or ovariectomy (OVX), have demonstrated that replacing back E 2 can have clear beneficial effects in stroke, neurodegeneration, cognitive, anxiety and depression indices of females (11) (12) (13) (14) . These effects in rodent models and the clinical data may be explained by the health of the system, and regimen and dosing of E 2 therapy used; however, a discussion of this is beyond the scope of this review and is provided elsewhere (15) . Thus, the various effects of E 2 throughout the lifespan, and in several systems that may influence disease states (e.g. stroke, cardiovascular disease, cognitive decline, neurodegeneration, mood ⁄ anxiety, osteoporosis, cancer, metabolic syndrome, etc.), support studies to investigate the mechanisms of the functional effects of E 2 .
Utility of an animal model to investigate the effects of E 2 
and its mechanisms
Despite the numerous effects of E 2 throughout the lifespan, and clear negative effects when E 2 precipitously declines at menopause for many women, the mechanisms of E 2 for its functional effects are not entirely clear. Although the clinical literature has provided insights into the nature of E 2 decline and its replacement, there are differences in responsiveness to E 2 among women that depend on many factors (age, prior E 2 experience, health, socio-economic status, social support, etc.). As such, investigating the mechanisms of the effects of E 2 in an animal model in which these potential factors can be controlled or manipulated is useful. Additionally, developing a model system in which both the psychological and physical effects of E 2 can be investigated simultaneously has been of interest. Described below are studies that we, and others, have carried out aiming to investigate the effects and mechanisms of E 2 in the body and brain using rodent models.
For the most part, the remainder of this review will focus on the effects of E 2 with respect to the adult female rodent, and the later portion of the developmental process. Studies that have characterised the nature of the functional effects of oestrogen so that potential mechanisms of these effects could be manipulated in subsequent studies will be reviewed. In these studies, the effects of E 2 covariation, extirpation and replacement for anxiety-like behaviour of rodents were determined. These studies were followed up by further investigating the dose-dependent effects of E 2 for behavioural processes, as well as growth in peripheral E 2 -sensitive tissues, such as the uterus and mammary tumours. Subsequent to this overview on the nature of the effects of E 2 , the mechanisms of oestrogens for these effects are discussed, with a primary focus on the actions of E 2 through the cognate ER, of which there are two cloned types: ERa and ERb. A focus will be on studies that have characterised the role of E 2 through ERb for beneficial psychological effects in animal models. This will be followed by a discussion of more recent studies in which the effects of E 2 in the brain were compared and contrasted with the effects of E 2 at ERs in peripheral tissues. Lastly, novel mechanisms of E 2 as well as other potential mechanisms downstream of ERs for these effects in animal models and ⁄ or in vitro models will be addressed. Given the profound effects of E 2 throughout the lifespan, it is imperative to have a greater understanding of its effects and mechanisms.
Nature of the effects of E 2
Nature of the effects of E 2 for anxiety-like behaviour To be able to initiate studies investigating the mechanisms of the effects of E 2 , it was necessary to first characterise the effects of E 2 in a rodent model. As spontaneously ovulating mammals, there are similarities in the endocrine cycles of women and rats. There is cyclical regulation of ovarian secretion of E 2 and progesterone following pulsatile hypothalamic gonadotrophin-releasing hormone and surges of pituitary follicle-stimulating hormone (FSH) and luteinising hormone (LH). There are species-specific differences in the cycles of women and rats and mice. For rats and mice, the average oestrous cycle length is 4 days (2, 16, 17) , whereas the average menstrual cycle length in women is 28 days (2). The oestrous cycle is divided into four phases: metoestrus, dioestrus, prooestrus and oestrus. Over the oestrous cycle LH and FSH levels are low and increase during pro-oestrus. E 2 rises during metoestrus, peaks during pro-oestrus, and is then decreased during oestrus. Progesterone increases during metoestrus and dioestrus, peaking for a second time during late pro-oestrus. The menstrual cycle occurs in three phases: follicular, luteal and menstrual (2) . During the follicular phase, LH and FSH gradually increase. E 2 increases during this phase and there is a surge in LH and FSH following peaking E 2 levels. During the luteal phase, progesterone levels increase and E 2 levels gradually wane following a precipitous decline post-ovulation. During menstruation, levels of progesterone and E 2 are low. Despite these general similarities in the endocrine control of the oestrous and menstrual cycles, there are robust differences in how these cycles are altered with ageing among women and rats. Menopause is characterised by changes in cyclicity followed by cessation in menstrual cycles and a decline in E 2 and progesterone levels. Conversely, in rats, the pattern of changes in cyclicity and E 2 and progesterone secretion, and reductions in reproductive-viability (i.e. reproductive senescence, which can be referred to as 'oestropause') (18) are more varied. In aged rats, there can be a pattern of persistent oestrus or persistent dioestrus. Generally, when cycling ceases among rats, E 2 levels decline to steady moderate levels and then increase (19, 20) , which is unlike the decline observed during menopause. Because of the similarities and differences between cyclicity and reproductive senescence in women and rats, several approaches to determine the role of E 2 for its functional effects in a rat model have been utilised. Generally, the classic behavioural neuroendocrinology approach of assessing hormonal covariation, extirpation, and replacement for a functional effect was utilised. First, young cycling and older reproductively senescent rats were behaviourally assessed during different E 2 (and progestin) milieu. Second, because E 2 co-varies with progestins during oestrus and there are differences in E 2 secretion with ageing and reproductive senescence, rats were OVX and replaced back with E 2 alone or not. Overall, what has been found is that physiological E 2 levels in plasma (Fig. 1, circles) occurred concomitant with greater anti-anxiety-like behaviour using the elevated plus maze of rats. The elevated plus maze is a well-validated bioassay of anxietyrelated behaviour in rodents in which an increase in time spent on the open arms is utilised as the primary behavioural index (21) . The details of the findings using this model are described below.
Role of E 2 covariation Figure 1 depicts the effects of natural covariation in E 2 levels among rats for behaviour in the elevated plus maze. Young adult rats in pro-oestrus (when naturally sexually-receptive) and, in late pregnancy, spent more time in the open arms of the plus maze, compared to rats in the dioestrous stage of the oestrous cycle or in late pregnancy, respectively. Furthermore, time spent on the open arms of the plus maze decline with ageing ⁄ reproductive senescence, as indicated by the behavioural responses of middle-aged (12-14 months old) rats coincident with lower E 2 levels in these subjects. Thus, variations in natural E 2 levels can alter anxiety-like behaviour of rats.
Role of E 2 extirpation and replacement
To further determine the extent to which E 2 alters anxiety-like behaviour of rats, rats were OVX and replaced-backed with placebo vehicle or E 2 regimen that mimics the oestrous cycle rise in E 2 . As depicted in Fig. 1 , OVX rats had low levels of open arm exploration, coincident with low E 2 levels, similar to dioestrous rats. Replacement of E 2 alone, or with progesterone (P 4 ; which co-varies with E 2 across endogenous cycles), similarly increased open arm time compared to vehicle administration to OVX rats. Thus, these data show that E 2 alone can have anti-anxiety-like effects among rats.
Nature of the actions of E 2 for trophic effects in the body
As discussed above, physiologically-relevant levels of E 2 reduce anxiety-like behaviour, although the extent to which E 2 has physical effects in this animal model needed to be examined. We developed a breast cancer-relevant model in which some rats were exposed to a chemical carcinogen [7,12- Plasma E 2 levels (pg/ml) D i o e s t r u s P r o -o e s t r u s E a r l y p r e g n a n c y L a t e p r e g n a n c y N o n -s e n e s c e n t S e n e s c e n t Open arm time (secs + sem) * * * * Adult female rats were tested at different stages of the oestrous cycle (dioestrus versus pro-oestrus), pregnancy (early versus late pregnancy), and ageing (mid-aged nonsenescent versus reproductively senescent), or following ovariectomy (OVX) and replacement back with E 2 and progesterone (P 4 ), or E 2 . *, depicts a P-value of P < 0.05 compared to respective control groups in each comparison. Circles depict plasma E 2 levels as measured by radioimmunoassay of rats in these conditions.
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were administered weekly injections of E 2 at low, dioestrous-like (0.03 mg ⁄ kg), or physiological, pro-oestrous-like (0.09 mg ⁄ kg) concentrations, or placebo vehicle (22, 23) . Rats were behaviourallytested weekly, and had tumours, if present, and uteri collected and weighed at the end of the study (22, 23) . As depicted in Fig. 2 , E 2 , at both dosages, increased uterine weight (a typical bioassay of E 2 action). E 2 dose-responsively increased tumour weight, an effect potentiated with carcinogen exposure, compared to OVX, vehicleadministered control rats (Fig. 2) . In these rats, we also saw a clear dose-dependent effect of E 2 for depression-like behaviour. Rats administered E 2 regimen that produces pro-oestrous-like E 2 levels had decreased immobility in the forced swim test compared to OVX vehicle-administered rats (22) . This study demonstrated the utility of simultaneously investigating the psychological and physical effects of E 2 in a rat model.
Together, these data demonstrate that some of the functional effects of E 2 in E 2 -responsive tissues (i.e. uterus, mammary tumours and the brain) may be dissociated from each other. Indeed, these studies supported further investigation of the mechanisms of the effects of E 2 using this integrated animal model that assesses peripheral trophic and CNS effects (22, 23) .
Mechanisms of the effects of E 2 : actions at ERs

General actions of ERs
The traditional view of the mechanisms of E 2 is akin to that of the other steroid hormones (e.g. progestins, androgens). That is, steroids act by binding to their intracellular steroid receptors, which form a steroid receptor complex that dimerises, enters the nucleus, binds DNA, alters gene expression and, ultimately, produces changes in cell (and organism) behaviour. In this regard, E 2 is known to have effects through at least two classic ER subtypes that have been identified to date, which are referred to as ERa and ERb. There is some indication that E 2 can also regulate gene expression irrespective of actions at these receptors. A discussion of these ER-independent actions will be addressed the end of this review. Of great interest is that ERa and ERb are widely (and differentially) distributed throughout the CNS and body, suggesting that some of the specificity of the various actions of E 2 are through binding to ERa versus ERb.
ER distribution in the body
Generally, ERa is widely expressed throughout most E 2 -sensitive tissues (whereas ERb expression is more circumscribed) in the body, which may underlie some of the physical effects of E 2 . It may be that increased expression of ERa in the uterus and mammary glands underlies the unwanted proliferative effects of E 2 in these tissues (24, 25) . By contrast, the effects of ERb in peripheral tissues may not underlie these negative proliferative effects. In support, although ERb is typically not expressed at high levels in mammary glands, prognosis in women with breast cancer whom have a greater expression of ERb is more favourable than those with lower ERb expression (26) . As well, there is greater expression of ERb in bone and ovaries than there is of ERa. Together, the differences in expression in these tissues suggest a potential role of therapeutics acting at ERb for many disease states, such as polycystic ovarian syndrome, osteoporosis and breast cancer (24, 27) . . Dose-dependent effects of oestradiol (E 2 ) to ovariectomised rats administered the chemical carcinogen (7,12-dimethylbenz(a)anthracene; DMBA), or not, for uterine growth and tumourigenesis of rats. As depicted at the bottom, rats were ovariectomised and exposed to a chemical carcinogen, or not. Rats were then primed weekly with vehicle or one of two dosages of E 2 (0.03 mg ⁄ kg, which produces low, dioestrous-like E 2 levels, or 0.09 mg ⁄ kg, which produces physiological, pro-oestrous-like E 2 levels), and behaviourally-tested (22) . At the end of the study, uteri and tumours (if present) were collected and assessed. Bars depict uterine and tumour mass as a percent of ovariectomised, vehicle-administered control rats. Pictures above bars are a representative photo of tissue in that condition.
ER distribution in the brain
There are differences in distribution of ERs in the CNS. For example, ERs are expressed in the hypothalamus, but can have clear differences in the specific regions in which they are expressed and the behavioural responses that may be related to the actions of E 2 in these regions. ERa, compared to ERb, is highly expressed in the ventrolateral, ventral medial and dorsal medial hypothalamus, and arcurate nucleus, and effects of E 2 for sexual behaviour may be important in some of these nuclei (28) . By contrast, ERb is more widely expressed in the paraventricular nucleus of the hypothalamus, on corticotrophin-releasing factor neurones, and this pattern of expression may be related to the effects of ERb for HPA function (28, 29) . Results of studies comparing the expression of ER subtypes across brain regions are of interest because there is clearly greater expression of ERb than ERa in the hippocampus (28) , which is a well-known limbic stricture involved in affective and cognitive regulation. Given the clear effects of E 2 for these hippocampusmediated behaviours, we hypothesised that some of the effects of E 2 with respect to anxiety and depression-like behaviour were a result of the actions at ERb in the hippocampus (30) . Studies addressing the role of ERb for its functional effects through actions in the hippocampus are described below.
The role of ERb in the hippocampus
A series of experiments to test this hypothesis and determine the role of ERb in the hippocampus for the effects of E 2 on anxietyand ⁄ or depression-like behaviour was conducted. A summary of the major findings from these experiments is depicted in Fig. 3 .
ERb knockout mice
To investigate the requirement of ERb, anxiety-like behaviour of mice lacking ERb was compared to their wild-type counterparts. Mice were OVX and administered E 2 (which acts at both ERa and ERb similarly) or a selective oestrogen receptor modulator (SERM) that has greater affinity for ERb than ERa, diarylpropionitrile (DPN), or vehicle. As depicted in Fig. 3 , E 2 and DPN similarly increased anti-anxiety-like behaviour in the elevated plus maze of wild-type, but not ERb knockout mice (bERKO), compared to OVX, vehicle-administered wild-type mice (31) . Additionally, we have found that wild-type, but not bERKO mice, have improved performance in cognitive or affective tasks that are mediated by the hippocampus, when in pro-oestrus (32). Although we did not investigate the effects of these manipulations for anxiety-like responding in ERa knockout mice in these studies, the literature demonstrates that ERa knockout mice would behave similarly as wild-type controls in anxiety measures (33) . Indeed, studies in knockout mice suggest that knockout of ERa, rather than ERb, may have greater effects on general arousal ⁄ motor behaviour and social behaviours (34) (35) (36) . These investigations lend support to findings in other laboratories that have shown the importance of ERb for anxiety and depression responding in female mice (33, 37, 38) . Indeed, in a recent report, it has been suggested that ERb may be particularly important for the anti-anxiety effects of physiological E 2 , rather than the anxiogenic effects of E 2 when in high and ⁄ or sustained concentrations (39) . Taken together, these studies demonstrate that ERb knockout in mice can regulate anxietylike responding to oestrogens. Recently, an interest has been whether some of the individual differences in responses to hormone replacement therapies may be related to the mechanisms of the treatment used. We have begun investigating this by administering the most commonly-prescribed E 2 therapy in the US, conjugated equine oestrogens (CEE), in our rodent models (41) . CEE is composed of approximately fifty compounds, only one of which is E 2 , so determining its mechanisms of action to improve its efficacy can be a challenge. In vitro studies have demonstrated that there is more robust neuroprotective effects with specific oestrogens contained in CEE than in others (40) . We have found that middle-aged rats have improved cognitive, anxiety, and social behaviour when administered CEE compared to vehicle (41) , although the mechanisms for this effect are not entirely understood and are presently under investigation. A recent study in our laboratory has investigated this question in OVX wildtype and bERKO mice and found that only wild-type mice had anti-anxiety-like effects of CEE (Fig. 3) . Thus, it may be that ERb is important for the anti-anxiety effects of CEE and investigations are ongoing to elucidate this further.
ERb antisense oligonucleotides
Although transgenic and knockout murine technologies have advanced the field of neuroendocrinology, there are always concerns about potential compensatory mechanisms and ⁄ or develop- Fig. 3 . Anti-anxiety-like behaviour of mice and rats following treatment with oestradiol (E 2 ) or selective oestrogen receptor modulators (SERMs) may be due to actions of oestrogen receptor (ER)b. Bars depict time spent on the open arms of the plus maze of adult female mice or rats as a percentage of ovariectomised controls. Wild-type (WT), but not ERb knockout (bERKO), mice treated with E 2 , an ERb-SERM (diarylpropionitrile; DPN), or a clinically-prescribed E 2 mimetic (conjugated equine oestrogens; CEE), had increased anti-anxiety-like behaviour. Ovariectomised, E 2 -primed rats administered scrambled control (control AS) or antisense oligonucleotides targeted against ERa (ERa AS), but not ERb (ERb AS), had increased anti-anxiety-like behaviour. Subcutaneous (s.c.) or hippocampal administration of E 2 or DPN, but not an ERa-SERM (propyl pyrazole triol; PPT), similarly increased antianxiety-like behaviour of ovariectomised rats. *P < 0.05 compared to respective control groups in each comparison. mental effects of gene mutation or deletion for behavioural responses. As well, the gene is deleted throughout the brain and body. To begin to investigate the temporal-and site-specificity of the ERb effect, we used intracerebroventicular administration of antisense oligonucleotides (AS-ODNs) targeted against ERa or ERb, versus saline or scrambled control, AS-ODNs to OVX, E 2 -primed rats (42) . We found that ERb AS-ODNs, but not saline, or scrambled or ERa AS-ODNs, during E 2 -priming, attenuated anti-anxiety behaviour in the plus maze (Fig. 3) (42) . We also determined that this treatment reduced expression of ERb in the hippocampus, but not ventral medial hypothalamus (control site), concomitant with this behavioural response (42) . Thus, knocking down ERb expression in the hippocampus reduces the anti-anxiety-like effects of E 2 among rats.
SERMs
In addition to using these genetic techniques to block a behavioural response that may be related to ERb action, we and others have also determined the effects of selectively activating ERa or ERb in the hippocampus, as described as follows. A summary of these data are depicted in Fig. 3 . We, and others, found similar effects of E 2 or DPN, but not an ERa SERM (propyl pyrazole triol; PPT), to increase anti-anxiety-and anti-depressive-like behaviour of OVX rats when these compounds were administered subcutaneously (i.e. the whole brain) (43) (44) (45) and directly to the hippocampus (46) . In a recent study, a week of once daily administration of DPN, its biologicallyactive S-enanitomer, or another ERb agonist, WAY-200070, to OVX rats produced anti-depressant-like effects in the forced swim test (47) . Although this review focuses on the literature in females, it must be noted that there may be sex differences and a role of gonadal status in the ERb-mediated effect. A previous study demonstrated that DPN reduces anxiety-like responding of gonadectomised rats (43) . However, a recent study failed to find such an effect of subcutaneous or oral administration of DPN to gonadallyintact male rats (48) . Determining whether the magnitude of the action of ERb depends upon neuroendocrine context is of interest. Taken together, these experiments in female mice and rats supported our hypothesis that ERb in the hippocampus is a target of the beneficial effects of E 2 for affective functions. Of further importance is that similar beneficial effects of ERb SERMs were observed when administered in a regimen that would affect the whole body and brain as well as when administered directly to the brain. Thus, these data lend support to the notion that the effects of oestrogens through ERb in the hippocampus may be dissociable from effects of oestrogens in peripheral tissues.
Mechanisms of the effect of E 2 : potential nontraditional actions
Rapid effects of E 2
In addition to having traditional actions at intracellular ERs, E 2 may also have some functional effects involving rapid actions at the membrane, alone, or to potentiate subsequent intracellular ER actions. Traditional effects of E 2 typically have latencies greater than 10-15 min, which is the time necessary to initiate gene transcription and protein synthesis. However, more rapid behavioural effects of E 2 have been described, suggesting that E 2 may have actions at the plasma membrane (30, 49) . For example, in the study described above investigating the effects of direct administration of E 2 and SERMs to the hippocampus, compounds were administered 10 min before behavioural testing (46) . Notably, these behavioural effects were similar as was observed in rats administered E 2 or SERMs 44-48 h before behavioural testing (45) . Thus, there can be rapid actions of oestrogens.
Membrane targets for E 2
The rapid actions of oestrogens may occur at the membrane. Restricting the actions of E 2 to the membrane, by administering E 2 conjugated to a large molecule (bovine serum albumin), similarly increases performance in the inhibitory avoidance task as does free E 2 which readily crosses into the cell (30, 50) . There are various potential membrane targets for E 2 for its nontraditional effects. The first possibility is that ERs may be associated with the membrane. There is some evidence that ERs, in particular ERa, can associate with caveolae, and interact with a G-protein-coupled receptor (GPCR) (51) . In vitro studies have demonstrated that E 2 may spur ERb to translocate to the cell membrane rapidly and transiently (52) . Moreover, other membrane receptors as targets of E 2 action have been suggested, such as ER-X (53), GPR30 (54) or Gq-mER (55, 56) . The functional significance of E 2 acting at these receptors is not entirely understood, but recent studies have pursued this question. As an example, a compound that is selective for the Gq-mER, but does not bind the ER, STX, was developed and its functional effects are being characterised. STX reduces weight gain in female guinea pigs, which is typically observed following OVX in a dose-related manner (55, 56) . Thus, there may be functional effects of oestrogens at a membrane-associated ER.
Additionally, the actions of E 2 may involve interactions with other GPCR or ion-gated neurotransmitter receptors. Receptors of particular interest are serotonin, glutamate, GABA, acetylcholine and dopamine (57) because of their clear relationship to mood and cognition. Several elegant studies have been performed aiming to investigate the interactions between ERb, the serotonin system and the hypothalamic-pituitary-adrenal axis, as related to affective responding. These are briefly reviewed below. In support, a high percentage of serotonin cells in the dorsal raphe nucleus co-express ERb (58) . DPN, administered once daily for 8 days, subcutaneously or to the dorsal raphe nucleus, increased expression of tryptophan hydroxylase mRNA in the dorsal raphe nucleus, as well as reducing depression-like responses of OVX rats (59) . Furthermore, ERb knockout mice have reductions in serotonin levels and expression of tryptophan hydroxylase mRNA in the dorsal raphe nucleus (37, 60) . In addition to these actions involving the serotoninergic system, ERb activation may reduce HPA responding. Unlike administration of E 2 and PPT, DPN decreases corticosterone levels when adminis-tered centrally or systemically (43, 47) . There is high expression of ERb in the paraventricular nucleus of female rats compared to ERa expression (61) . As well, E 2 and PPT, but not DPN, increase the expression of the immediate early gene c-fos in the paraventricular nucleus following a stressor (29, 47) . Thus, these studies demonstrate the role of oestrogens at neurotransmitter and neuromodulator targets.
It may also be that the functional effects of E 2 occur downstream of its actions to alter neurosteroidogenesis. E 2 can enhance activity of steroid metabolism enzymes, produce de novo P4 synthesis in astrocytes, and increase 3a,5a-THP concentrations in the hippocampus and other brain regions relevant for affect and cognition (62) (63) (64) . Finally, it may be that there is a potentiation of intracellular ER signalling following activation of a membrane process. Lordosis behaviour is a well-characterised bioassay for steroid actions, and is a clear example of a behaviour modulated by the traditional actions of E 2 at ERs (65). However, more recent studies have demonstrated that signalling of E 2 at the membrane enhances subsequent effects in the hypothalamus to facilitate lordosis of OVX rats (66) . The potential interactions between these membrane targets and ERb for affective and cognitive processes and trophic effects in the body are being investigated.
Targets downstream of the membrane for E 2
The effects of E 2 at the membrane interact with several molecular pathways, and the multitude effects of E 2 through these membrane targets, described above, have been extensively reviewed (30, 51, 56, 66, 67) . In support, E 2 can have interactions with other transcription factors (e.g. pCREB, STATs, Elk-1-Srf, ATF-2-Jun), growth factors, as well as initiate major signalling pathways [e.g. phospholipase C, phosphatidylinositol 3 kinase and mitogen-activated protein kinase (MAPK)] (51, 68, 69) . We have found that pharmacologically blocking MAPK in the hippocampus of OVX rats attenuates the effects of E 2 to improve inhibitory avoidance performance (30) . Of interest are the other functional effects of the interactions of E 2 with these targets, and their role in our model investigating the mechanisms of E 2 in the CNS and in peripheral E 2 -sensitive tissues.
What other actions are there in addition to ERb: potential role of cyclin D1 and ⁄ or histones in E 2 -sensitive tissues
SERMs' effects in the hippocampus versus uterus versus mammary tumours
The downstream mechanisms of ERa and ERb for effects on proliferation in the body and possible trophic effects in the brain are of interest. To this end, studies investigating the behavioural effects of subcutaneously administered SERMs for behaviour were replicated and extended to investigate the peripheral effects of SERMs. As described above, rats were OVX and administered the chemical carcinogen (DMBA) or not. Rats were administered E 2 , PPT, or DPN once a week for 13 weeks. Behavioural analyses occurred weekly, and brains, tumours (if present), and uteri were collected at the end of the study. As depicted in Fig. 4 , the ERa-SERM, PPT, increased tumour incidence and uterine weight, similar to that observed with E 2 . The ERb-SERM, DPN, did not have these effects for tumourigenesis or uterine proliferation; yet, E 2 and DPN similarly increased anti-anxiety behaviour (Fig. 4) . Thus, a possibility is that ERb may not be associated with proliferative effects in the body to the same extent as ERa. This study also demonstrates that behavioural and peripheral effects of oestrogens can be dissociated. Further investigation of these mechanisms is ongoing. Recent investigations have focused on changes in the cell cycle that may underlie these ERa-and ERb-specific actions in the hippocampus, uterus, and mammary tumours.
Role of cyclin D1
In Dr. Cheryl Frye's lab, we have begun investigating whether some of the functional effects of E 2 and SERMs involve changes in the cell cycle. As such, the expression of cyclin D1 in the uterus, tumours, and hippocampus has been investigated. Cyclin D1 is important for governing DNA synthesis and is considered a molecular mechanism driving tumourigenesis. Indeed, the cyclin D1 gene is overexpressed in 30-50% of breast cancer, despite not seeming to alter prognosis of the disease in women with ERa+ tumours (69) . Cyclin D1 is a positive regulator of ERa transcription, further implicating it in the proliferative effects of E 2 in the body. A recent in vitro study suggests that overexpression of cyclin D1 can reduce the efficacy of newly-developed SERMs to act as antagonists in breast cancer models (70) . Working with Dr. Jamie Rusconi, we have demonstrated differences in cyclin D1 expression in the body and brain in our animal model. As expected given its role in tumourigenesis, cyclin D1 expression was particularly increased in the tumours of rats administered E 2 and PPT compared to its expression in the uterus or hippocampus following vehicle or DPN administration (Fig. 4) . Thus, these data suggest that differences in cyclin D1 may be one target for further investigation of the trophic effects of oestrogens in the brain versus body.
Role of histone 3
Histone modifications (acetylation, methylation, phosphorylation, etc.), downstream of ERs, may underlie the divergent trophic effects in the body and brain. Recent studies have demonstrated a clear role of epigenetics in the hormonal control of organisation of the brain, and therefore behaviour (71) (72) (73) . In adulthood, histone modifications have also been shown to be important for hippocampal plasticity as related to fear and other learning processes (74, 75) . Histone modifications are also of interest to us given their role in tumour biology. In support, histone deacetylases (HDACs) modulate chromatin structure and transcriptional activity in the cell by altering acetylation of histones, in particular histone 3 and 4, in the nucleus. HDACs are also involved in regulating transcriptional pathways, by acting as repressors, important for differentiation and growth of cells. Because HDAC recruitment is typically associated with repression, HDAC inhibitors are candidates for cancer treatments owing to their ability to attenuate repression, and, therefore, promote expression of genes involved in cell differentiation and death, and cell cycle arrest. Recent experiments have begun analysing changes in histone 3 acetylation and phospho-acetylation in tissues from rats in our model. These results have suggested that there are differences in histone 3 acetylation and phospho-acetylation in the uterus, tumours, and hippocampus of rats administered E 2, PPT, DPN or placebo, and DMBA (Fig. 4) . In the hippocampus, phospho-acetylated form of histone 3 was reduced by E 2 , PPT and DPN similarly; however, acetylated histone 3 was increased by E 2 and DPN, and decreased by PPT, compared to vehicle. In tumours, both acetylated and phospho-acetylated histone 3 was increased by E 2 and PPT in particular. In the uterus, phospho-acetylated, but not acetylated, were increased by PPT more so than E 2 or DPN. These findings substantiate further the investigation of the effects of E 2 on histone modifications to underlie differential trophic effects on In ovariectomised rats exposed to a chemical carcinogen (7, 12 -dimethylbenz(a)anthracene; DMBA): (i) administration of oestradiol (E 2 ) increases tumourigenesis, uterine growth and anti-anxiety behaviour; (ii) administration of an ERa-selective oestrogen receptor modulator (SERM) (propyl pyrazole triol; PPT) increases tumourigenesis, uterine growth, but not anti-anxiety behaviour; and (iii) administration of an ERb-SERM (diarylpropionitrile; DPN) increases anti-anxiety behaviour, but not tumourigenesis or uterine growth. Images below are representative depictions from western blots of changes in protein expression in tumours, uterus and hippocampus [i.e. b-actin as a loading control, cyclin D1, phospho-acetylated histone 3 (pACH3), and acetylated histone 3 (AcH3)] of rats in these conditions. VEH, vehicle.
reproductive and neural tissue. How any beneficial effects are related to their capacity to alter histones and ⁄ or actions involving ERb needs to be investigated further.
Summary and conclusions
In a whole animal model, E 2 regimen that exert trophic effects to increase tumourigenesis and uterotrophic effects can enhance affective behaviour. E 2 , CEE supplement or ERb-SERM enhance affective behaviour, but ERb-SERMs have no trophic effects in the periphery. E 2 and ⁄ or ERb SERMs to wild-type, but not bERKO, mice enhance the affective behaviour of males and females, and investigation of trophic effects is ongoing. E 2 and ERb SERMs to hippocampus enhance affective behaviour without peripheral trophic effects. Some of these trophic effects in the periphery may be related to changes in cell cycle ⁄ division (cyclin D1) and ⁄ or histone modifications. Experiments such as these are timely because more information is needed in basic science studies to inform clinicallyrelevant questions, such as the effects of oestrogens on anxiety, mood, cognition, and proliferative processes that may confer an increased risk for reproductive cancers. Thus, it may be possible to differentiate the beneficial effects of oestrogens through ERb, particularly in the CNS, from negative proliferative effects on peripheral tissues. Studies are ongoing to investigate downstream targets of E 2 at ERb for its beneficial effects in the body and brain.
